Burfiralimab

CAS No. 2460809-80-5

Burfiralimab( —— )

Catalog No. M36776 CAS No. 2460809-80-5

Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 299 Get Quote
5MG 471 Get Quote
10MG 708 Get Quote
25MG 1030 Get Quote
50MG 1371 Get Quote
100MG 1782 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Burfiralimab
  • Note
    Research use only, not for human use.
  • Brief Description
    Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
  • Description
    Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2460809-80-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Prasenohadi Prasenohadi, et al. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11(11):2961.?
molnova catalog
related products
  • DVR-01

    DVR-01 is an HBV capsid inhibitor and can be used in studies about the treatment of Hepatitis B virus (HBV) infection and related conditions.

  • RO6889678

    RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure.

  • IR415

    IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression.